167 related articles for article (PubMed ID: 17966166)
1. Phase II study of gemcitabine combined with platinum chemotherapy for recurrent epithelial ovarian cancer.
Peng P; Shen K; Yang JX; Wu M; Huang HF; Pan LY; Lang JH
Chin Med Sci J; 2007 Sep; 22(3):177-82. PubMed ID: 17966166
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
[TBL] [Abstract][Full Text] [Related]
3. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Elshebeiny M; Almorsy W
J Egypt Natl Canc Inst; 2016 Sep; 28(3):183-9. PubMed ID: 27237370
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients.
Chanpanitkitchot S; Tangjitgamol S; Khunnarong J; Thavaramara T; Pataradool K; Srijaipracharoen S
Asian Pac J Cancer Prev; 2014; 15(13):5215-21. PubMed ID: 25040977
[TBL] [Abstract][Full Text] [Related]
7. [Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Chu P; Lu CH; Sheng XG; Zhou CX; Li DP; DU XL; Liu NF
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):808-12. PubMed ID: 21211276
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
Vici P; Sergi D; Pizzuti L; Mariani L; Arena MG; Barba M; Maugeri-Saccà M; Vincenzoni C; Vizza E; Corrado G; Paoletti G; Tomao F; Tomao S; Giannarelli D; Di Lauro L
J Exp Clin Cancer Res; 2013 Aug; 32(1):49. PubMed ID: 23927758
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
Kose MF; Sufliarsky J; Beslija S; Saip P; Tulunay G; Krejcy K; Minarik T; Fitzthum E; Hayden A; Melemed A
Gynecol Oncol; 2005 Feb; 96(2):374-80. PubMed ID: 15661224
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
[TBL] [Abstract][Full Text] [Related]
14. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Seliger G; Mueller LP; Kegel T; Kantelhardt EJ; Grothey A; Groe R; Strauss HG; Koelbl H; Thomssen C; Schmoll HJ
Int J Gynecol Cancer; 2009 Nov; 19(8):1446-53. PubMed ID: 20009905
[TBL] [Abstract][Full Text] [Related]
17. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
Ferrero A; Logrippo V; Spanu PG; Fuso L; Perotto S; Daniele A; Zola P
Int J Gynecol Cancer; 2009 Dec; 19(9):1529-34. PubMed ID: 19955931
[TBL] [Abstract][Full Text] [Related]
19. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer.
Nogué M; Cirera L; Arcusa A; Batiste-Alentorn E; Balil A; Font A; Perez-Gracia JL; Carrasco EM; Tusquets I
Anticancer Drugs; 2002 Sep; 13(8):839-45. PubMed ID: 12394269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
